Beyin Omurilik S›v›s› Analizinde Güncel Yaklafl›mlar

Nöropsikiyatri Arflivi 2007; 44: 28-33
Archives of Neuropsychiatry 2007; 44: 28-33
Topçular ve ark.
Beyin-Omurilik S›v›s› Analizinde Güncel Yaklafl›mlar 33
Kaynaklar
1. Tanenbaum LN. Clinical 3T MR imaging: mastering the challenges.
Magn Reson Imaging Clin N Am. 2006; 14:1-15
2. Prince MR, Meaney JF. Expanding role of MR angiography in clinical
practice. 2006; 16: B3-8.
3. Sundgren PC, Dong Q, Gomez-Hassan D, et al. Diffusion tensor imaging
of the brain: review of clinical applications. 2004; 46: 339-50.
4. Reiber H. Flow rate of cerebrospinal fluid(CSF)- a concept common to
normal normal blood-CSF barrier and to dysfunction in neurological
diseases. J Neurol Sci 1994; 122: 189-203.
5. Reiber H, Peter JB. Cerebrospinal fluid analysis: disease related patterns
and evaluation programs. J Neurol Sci 2001; 184: 101-21.
6. Reiber H. CSF flow- Its influence on CSF concentration of brain-derived
and blood-derived proteins. In: Teelken A, Korf J, editors, Neurochemistry,
New York: Plenum, 1997, pp. 51-72.
7. Reiber H. Dynamics of brain proteins in cerebrospinal fluid. Clin Chim
Acta 2001; 310:173-86.
8. Keir G, Luxton RW, Thompson EJ. Isoelectric focusing of cerebrospinal
fluid immunoglobulin G: an annotated update. Ann Clin Biochem
1990; 27:436-43.
9. Regeniter A, Steiger JU, Scholer A, et al. Windows to the ward: graphically
oriented report forms. Presentation of complex, interrelated
laboratory data for electrophoresis/immunofixation, cerebrospinal
fluid, and urinary protein profiles. Clin Chem 2003; 49: 41-50.
10. Dorta-Contreras AJ, Reiber H. Molecular Diffusion/cerebrospinal
fluid flow theory. Rev Neurol 2004; 39: 564-9.
11. Link H, Tibbling G. Principles of albumin and IgG disorders. Evaluation
of IgG synthesis within the central nervous system in multiple sclerosis.
Scand J Clin Lab Invest 1997: 37: 397-401.
12. Tourtellote WW. On cerebrospinal fluid immunglobulin-G (IgG) quotients
in multiple sclerosis and other diseases. A review and a new
formula to estimate the amount of IgG synthesized per day by the
central nervous system. J Neurol Sci 1970; 10:279-304.
13. Reiber H, Otto M, Trendelenburg C, Wormek A. Reporting cerebrospinal
fluid data: knowledge base and interpretation software. Clin
Chem Lab Med. 2001; 39: 324-32.
14. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatry
central nervous system environment: migration, maintenence, local
antibody production, and therapeutic modulation. Ann Neurol. 2006;
59: 880-92.
15. Reiber H, Sindic CJM, Thompson EJ. Cerebrospinal fluid- clinical
neurochemistry of neurological diseases, Heidelberg: Springer, 2001.
16. Reiber. Evaluation of blood-CSF barrier function and quantification of
the humoral immune response within CNS. In: Thompson EJ, Trajano
M, Livrea P, editors, CSF analysis in multiple sclerosis, Milan: Springer,
1996, pp. 51-72.
17. Brettschneider J, Claus A, Kassubek J, et al. Isolated blood-cerebrospinal
fluid barrier dysfunction: prevelance and associated diseases.
J Neurol. 2005; 252: 1067-73.
18. Andersson M, Alvarez-Cermeno J, Bernani G et al. Cerebrospinal
fluid in the diagnosis of multiple sclerosis: A consensus report. J
Neurol Neurosurg Psychiatry 1994; 57: 897-902.
19. Freedman MS, Thompson EJ, Deisenahammer F et al. Arch Neurol
2005; 62: 865-70.
20. Felgenhauer K, Reiber H. The diagnostic significance of antibody spesificity
indices in multiple sclerosis and herpes virus induced diseases
of nervous system. Clin Invest 1992; 70: 28-37.
21. Peter JB, Bowman RL. Intra-blood-brain-barrier synthesis of IgG:
comparison of IgG synthesis formulae in a computer model and in
1.629 consecutive specimens. Neurology 1992; 42: 510-5.
22. Lawrence RH. The role of lumbar puncture as a diagnostic tool in
2005. Crit Care Resusc 2005; 7 :213-20.
23. Debiasi RL, Tyler KL. Molecular methods for diagnosis of viral encephalitis.
Clin Microbiol Rev 2004; 17: 903-25.
24. Peter JB. Use and interpretation of laboratory tests in neurology, 4th
ed, Santa Monica, CA: Specialty Laboratories, 1999.
25. Shah KH, Edlow JA. Distinguishing traumatic lumbar puncture from
true subarachnoid hemorrage. J Emerg Med. 2002; 23: 67-74.
26. Schumann GB, Crisman LG. Cerebrospinal fluid cytopathology. Clin
Lab Med 1985; 5: 275-302.
27. Avent J. Flow cytometry in body fluids analysis. Clin Lab Med. 1985; 5:
389-403.
28. Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau, A
beta, and phosphorilated tau protein for the diagnosis of Alzheimer
disease. J Cell Physiol 2006; 208: 39-46.
29. Overturf GD. Defining bacterial meningitis and other infections of the
central nervous system. Pediatr Crit Care Med. 2005; 6(3 suppl): S14-8.
30. Kleine TO, Benes L, Zofel P. Studies of the brain specificity of s100b
and neuron-specific enolase (NSE) in blood serum and acute care
patients. Brain Res Bull. 2003; 61: 265-79.
31. Kosmas C, Tsavaris NB, Soukouli G, et al. Changes of cerebrospinal
fluid tumor marker levels may predict response to treatment and survival
of carinomatous meningitis in patients with advanced brest cancer.
Med Oncol. 2005; 22: 123-8.
32. Wiltfang J, Lewczuk P, Reiderer P, et al. Consensus paper on the
WFSBP Task Force on Biological Markers of Dementia: the role of
CSF and blood analysis in the early detection and differential diagnosis
of dementia. World J Biol Psychiatry. 2005; 6: 69-84.
33. Wallin AK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for
Alzheimer’s Disease: levels of beta-amyloid, tau, phosphorilated tau
relate to clinical symptoms and survival. Dement Geriatr Cogn Disord.
2006; 21: 131-8.